Disc Medicine reports Q3 2025 results with cash position of $616 million
Reuters
Nov 06, 2025
<a href="https://laohu8.com/S/IRON">Disc Medicine</a> reports Q3 2025 results with cash position of $616 million
Disc Medicine Inc. reported cash, cash equivalents, and marketable securities of $615.9 million as of September 30, 2025. In October 2025, the company completed a public offering with net proceeds of approximately $211 million, which is expected to extend its cash runway into 2029. Research and development expenses were $50.3 million for the third quarter of 2025, up from $24.7 million in the same period of 2024, primarily due to the progression of clinical programs and a $10.0 million milestone payment related to the DISC-3405 program. Key business developments included the submission of a New Drug Application for bitopertin in erythropoietic protoporphyria, initiation of a Phase 1b study of DISC-3405 in sickle cell disease, and ongoing Phase 2 studies in polycythemia vera and myelofibrosis.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569813-en) on November 06, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.